Biotech Values

[Biowatch]

Cramer featured NSTK on Halloween, price up as a result.

http://www.cnbc.com/id/15840232?video=583986002&play=1

He said it was pummeled because it missed earnings, but I'm not sure how many people trade development stage biotechs based on "earnings." I think it was the resounding silence on a milestone payment from PG for moving PTH into clinical trials that left a hole in revenues, plus the fact that they increased spending on research and trials which don't have outsidde funding that hurt. So, okay, maybe this counts as an "earnings" miss..